tnik

TNIK-IN-7 is a potent and selective Traf2 and Nck interacting kinase (TNIK) inhibitor (IC50: 11 nM) with antitumor activity for studying signaling and proliferation in colorectal cancer cells.

NCB-0846 is an orally active TNIK inhibitor (IC50: 21 nM).

TNIK-IN-3 is a highly potent and orally active inhibitor of Traf2- and Nck-interacting protein kinase (TNIK). It exhibits a strong selectivity for TNIK with an IC50 value of 0.026 μM. Additionally, TNIK-IN-3 demonstrates inhibitory activity against Flt4 (IC50 = 0.030 μM), Flt1 (IC50 = 0.191 μM), and DRAK1 (IC50 = 0.411 μM). This compound holds potential for carrying out research on colorectal cancer (CRC) [1].

TNIK-IN-2 is an inhibitor Traf2- and Nck-interacting protein kinase (TNIK, IC50 = 1.33 μM)) which is a downstream signal protein of the Wnt β-catenin pathway.

TNIK-IN-5 is an potent TNIK inhibitor (IC50= 0.05 μM). TNIK-IN-5 potently inhibits Wnt signaling in intact cells. TNIK-IN-5 exhibits excellent in vitro anti-colorectal cancer activity.

TNIK-IN-1 is an inhibitor of Traf2- and Nck-interacting kinase (TNIK).

TNIK-IN-4, a powerful TNIK inhibitor, exhibits an IC50 value of 0.61 μM. Furthermore, it demonstrates inhibitory effects on the HCT116 cell line, which is representative of colorectal cancer [1].

TINK-IN-1 is a selective and potent TNIK inhibitor (IC50: 8 nM).TINK-IN-1 inhibits colorectal cancer cell viability and can be used to study mental retardation.

TNIK&MAP4K4-IN-1 (compound A-39) is a potent dual inhibitor of TNIK and MAP4K4 HGK, with IC50 values of 1.29 nM and <10 nM, respectively, in human hepatic stellate cell LX-2, and is applicable in cancer and fibrosis inhibition [1].

TNIK-IN-6 (Compound 9) acts as an inhibitor of Traf2 and Nck-interacting kinase (TNIK), with an IC50 of 0.93 μM, a kinase implicated in various neurological and psychiatric disorders [1] [2].

Robotnikinin is an Shh signaling inhibitor in a concentration-dependent manner. It acts by exhibiting significant repression of Shh-induced Gli1/Gli2.

Delequamine (RS 15385-197) is a selective and potent TNIK inhibitor (IC50: 8 nM).TINK-IN-1 inhibits colorectal cancer cell viability and can be used to study mental retardation.

KY-05009 is a chemical compound that effectively suppresses TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells, reduces TNIK protein expression and the transcriptional activity of Wnt target genes, and promotes apoptosis in cancer cells, displaying anti-cancer properties. Furthermore, it functions as an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a Ki of 100 nM.

Pim1 AKK1-IN-1 (LKB1 AAK1 dual inhibitor) is a potent multi-kinase inhibitor with Kd values of 35 nM 53 nM 75 nM 380 nM for Pim1 AKK1 MST2 LKB1 respectively, and also inhibits MPSK1 and TNIK.

DMX-5804 is a potent, selective MAP4K4 inhibitor, with an IC50 of 3 nM.DMX-5804 enhances cardiomyocyte survival, and reduces ischemia-reperfusion injury in mice.

PF-06279794 is a potent, selective and ATP-competitive TNIK inhibitor.

PF-06260933 Dihydrochloride is a MAP4K4 (HGK) inhibitor (IC50 = 140 nM). It can improve the fasting hyperglycemia in mice. In addition, it inhibited Mink and Tnik (IC50 values of 8 and 13 nM, respectively).

MAP4K4 (HGK) inhibitor (IC50 = 140 nM). Also inhibits MINK and TNIK (IC50 values are 8 and 13 nM, respectively). Improves fasting hyperglycemia in mice. Orally active. Ammirati et al (2015) Discovery of an in vivo tool to establish proof-of-concept for MAP4K4-based antidiabetic treatment. ACS Med.Chem.Lett. 6 1128 PMID:26617966

ON 108600 is a chemical inhibitor targeting CK2 (Casein Kinase 2), TNIK, and DYRK1, demonstrating IC50 values of 0.016 μM and 0.007 μM for DYRK1A and DYRK1B, 0.028 μM for DYRK2, 0.05 μM and 0.005 μM for CK2α1 and CK2α2, and 0.005 μM for TNIK, respectively. This compound exhibits antitumor activity [1].

INS018 055 (TNIK&MAP4K4-IN-2) is a highly efficient TNIK and MAP4K4 inhibitor with antifibrotic activity. It can be used in research on idiopathic pulmonary fibrosis.